171 related articles for article (PubMed ID: 38003967)
1. General Clinico-Pathological Characteristics in Glioblastomas in Correlation with p53 and Ki67.
Sipos TC; Kövecsi A; Ovidiu-Ioan Ș; Zsuzsánna P
Medicina (Kaunas); 2023 Oct; 59(11):. PubMed ID: 38003967
[No Abstract] [Full Text] [Related]
2. Diagnostic algorithm for pathological evaluation of gliomas in a resource-constrained setting.
Jain S; Gupta P; Shankar KB; Singh R; Siraj F
J Cancer Res Ther; 2023; 19(3):562-566. PubMed ID: 37470575
[TBL] [Abstract][Full Text] [Related]
3. Practice of IDH1, ATRX, and P53 Immunohistochemistry in Integrated Diagnosis of Adult Diffuse Gliomas: Single Center Study.
Shabanzadeh Nejabad Z; Mabroukzadeh Kavari H; Saffar H; Tavangar SM; Sefidbakht S; Khoshnevisan A; Zare-Mirzaie A; Vasei M; Jafari E; Yaghmaii M; Saffar H
Appl Immunohistochem Mol Morphol; 2023 Jul; 31(6):390-398. PubMed ID: 37278280
[TBL] [Abstract][Full Text] [Related]
4. Utility of ATRX immunohistochemistry in diagnosis of adult diffuse gliomas.
Ikemura M; Shibahara J; Mukasa A; Takayanagi S; Aihara K; Saito N; Aburatani H; Fukayama M
Histopathology; 2016 Aug; 69(2):260-7. PubMed ID: 26741321
[TBL] [Abstract][Full Text] [Related]
5. Reliability of IDH1-R132H and ATRX and/or p53 immunohistochemistry for molecular subclassification of Grade 2/3 gliomas.
Nishikawa T; Watanabe R; Kitano Y; Yamamichi A; Motomura K; Ohka F; Aoki K; Hirano M; Kato A; Yamaguchi J; Maeda S; Kibe Y; Saito R; Wakabayashi T; Kato Y; Sato S; Ogino T; Natsume A; Ito I
Brain Tumor Pathol; 2022 Jan; 39(1):14-24. PubMed ID: 34826036
[TBL] [Abstract][Full Text] [Related]
6. [Application of ATRX in diagnosis and prognostic evaluation of glioma].
Li Z; Piao YS; Zhang LY; Wang LM; Wang DD; Fu YJ; Cai YN; Lu DH
Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):690-694. PubMed ID: 29050070
[No Abstract] [Full Text] [Related]
7. Pineal region glioblastomas display features of diffuse midline and non-midline gliomas.
D'Amico RS; Zanazzi G; Wu P; Canoll P; Bruce JN
J Neurooncol; 2018 Oct; 140(1):63-73. PubMed ID: 29992434
[TBL] [Abstract][Full Text] [Related]
8. The importance of IDH1, ATRX and WT-1 mutations in glioblastoma.
Gülten G; Yalçın N; Baltalarlı B; Doğu G; Acar F; Doğruel Y
Pol J Pathol; 2020; 71(2):127-137. PubMed ID: 32729303
[TBL] [Abstract][Full Text] [Related]
9. ATRX loss in glioneuronal tumors with neuropil-like islands indicates similarity to diffuse astrocytic tumors.
Kakkar A; Nambirajan A; Kaur K; Kumar A; Mallick S; Suri V; Sarkar C; Kale SS; Garg A; Sharma MC
J Neurooncol; 2016 Oct; 130(1):63-68. PubMed ID: 27469217
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemistry on IDH 1/2, ATRX, p53 and Ki-67 substitute molecular genetic testing and predict patient prognosis in grade III adult diffuse gliomas.
Takano S; Ishikawa E; Sakamoto N; Matsuda M; Akutsu H; Noguchi M; Kato Y; Yamamoto T; Matsumura A
Brain Tumor Pathol; 2016 Apr; 33(2):107-16. PubMed ID: 26968173
[TBL] [Abstract][Full Text] [Related]
11. Radiogenomics correlation between MR imaging features and major genetic profiles in glioblastoma.
Hong EK; Choi SH; Shin DJ; Jo SW; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SH; Won JK; Kim TM; Park CK; Kim IH; Lee ST
Eur Radiol; 2018 Oct; 28(10):4350-4361. PubMed ID: 29721688
[TBL] [Abstract][Full Text] [Related]
12. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.
Reuss DE; Sahm F; Schrimpf D; Wiestler B; Capper D; Koelsche C; Schweizer L; Korshunov A; Jones DT; Hovestadt V; Mittelbronn M; Schittenhelm J; Herold-Mende C; Unterberg A; Platten M; Weller M; Wick W; Pfister SM; von Deimling A
Acta Neuropathol; 2015 Jan; 129(1):133-46. PubMed ID: 25427834
[TBL] [Abstract][Full Text] [Related]
13.
Meel M; Jindal A; Kumar M; Mathur K; Singh A
Asian J Neurosurg; 2024 Mar; 19(1):14-20. PubMed ID: 38751398
[No Abstract] [Full Text] [Related]
14. Significance of H3K27M mutation with specific histomorphological features and associated molecular alterations in pediatric high-grade glial tumors.
Bozkurt SU; Dagcinar A; Tanrikulu B; Comunoglu N; Meydan BC; Ozek M; Oz B
Childs Nerv Syst; 2018 Jan; 34(1):107-116. PubMed ID: 29063957
[TBL] [Abstract][Full Text] [Related]
15.
Barange M; Epari S; Gurav M; Shetty O; Sahay A; Shetty P; Goda J; Moyiadi A; Gupta T; Jalali R
Neurol India; 2021; 69(1):126-134. PubMed ID: 33642283
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical ATRX expression is not a surrogate for 1p19q codeletion.
Yamamichi A; Ohka F; Aoki K; Suzuki H; Kato A; Hirano M; Motomura K; Tanahashi K; Chalise L; Maeda S; Wakabayashi T; Kato Y; Natsume A
Brain Tumor Pathol; 2018 Apr; 35(2):106-113. PubMed ID: 29550880
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical expression of ATRX in gliomas.
Jalal JA; Rowandizy AIS; Ismael AT
Cell Mol Biol (Noisy-le-grand); 2020 Aug; 66(7):131-135. PubMed ID: 33287933
[TBL] [Abstract][Full Text] [Related]
18. Prediction of Ki-67 labeling index, ATRX mutation, and MGMT promoter methylation status in IDH-mutant astrocytoma by morphological MRI, SWI, DWI, and DSC-PWI.
Yang X; Hu C; Xing Z; Lin Y; Su Y; Wang X; Cao D
Eur Radiol; 2023 Oct; 33(10):7003-7014. PubMed ID: 37133522
[TBL] [Abstract][Full Text] [Related]
19. ATRX regulates glial identity and the tumor microenvironment in IDH-mutant glioma.
Babikir H; Wang L; Shamardani K; Catalan F; Sudhir S; Aghi MK; Raleigh DR; Phillips JJ; Diaz AA
Genome Biol; 2021 Nov; 22(1):311. PubMed ID: 34763709
[TBL] [Abstract][Full Text] [Related]
20. ATRX immunostaining predicts IDH and H3F3A status in gliomas.
Ebrahimi A; Skardelly M; Bonzheim I; Ott I; Mühleisen H; Eckert F; Tabatabai G; Schittenhelm J
Acta Neuropathol Commun; 2016 Jun; 4(1):60. PubMed ID: 27311324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]